Anti-dyslipidemics - A tale of two launches

Anti-dyslipidemics achieved global sales of $21.7 billion in 2002, a growth rate of 12.5% over 2001. Due to the maturing of the market, evidenced by the increasing availability of generic statins, growth in this market has slowed in recent years. However, increasing prevalence of dyslipidemia and the launch of novel adjunctive therapies and statin single-pill combinations will drive future growth 

Scope

Evaluation of lifecycle management strategies employed to maximize revenue potential and brand life of agents in all anti-dyslipidemic classes 

Analysis of the impacts of patent expiries from 2003 to 2011 in the US, EU and Japan on all first and second generation statins 

Evaluation of the initial uptake of Crestor versus Zetia and the longer term potential of these agents over the forecast period to 2011 

Assessment of the expanding use of combination therapy, following the launch of novel adjunctive therapies and single-pill combination therapies 

Report Highlights

Due to loss of patent protection in the major markets, Datamonitor forecasts Zocor’s global sales to decline to $604m in 2011. In order to minimize this loss in sales, Johnson & Johnson MSD Consumer Pharmaceuticals has applied for OTC status for Zocor in the UK. However, this lifecycle-management strategy is unlikely to maintain Zocor’s revenues 

The increasing use of combination therapy will enable more patients to achieve target cholesterol goals. As a result, the development of statin single-pill combinations is an active lifecycle-management strategy being pursued by many statin manufacturers, with these therapies forecast to collectively achieve global sales of $4.7 billion in 2011 

Zetia and Crestor represent the newest anti-dyslipidemics to reach the US and EU and both agents have been aggressively marketed. The benefit of using Zetia in combination with statins has led to rapid initial uptake. However, Crestor has encountered a number of setbacks since launch and concerns over safety have led to slower initial uptake 

Reasons to Purchase

To prioritize sales and marketing efforts to effectively counter competitive threats 

To select best product lifecycle management strategies to counter generic competition and expand a drug’s commercial potential 

To optimize licensing decisions based on market potential for inline products and identify optimal R&D development strategies. 

January 2004 Pages: 319 

Publisher: Datamonitor Cardiovascular Reports 2004 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Cardiovascular_Reports_2004.html#a532